Prevention of Post Operative Ileus
Conditions
Brief summary
Perioperative Celecoxib to promote bowel movement and to reduce post-operative pain after elective colonic resection.
Detailed description
Post-operative ileus is a common surgical complication occurring in with up to 20% of patients, with a significant clinical and economical effect. Many preventative measures have been tested to promote gastrointestinal motility following intestinal surgery have been suggested. The medical intervention in the proposed study includes administration of a selective COX-2 inhibitor, specifically Celecoxib, in the peri-operative period following an elective colon resection. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic therapeutic effects. The drug is approved for use in by the ministry of health in Israel and in the United states. The study aims to assess the use of this widely used medication for evaluation of the clinical effect on post-operative bowel transit, as well as the drugs' effect on post-operative pain.
Interventions
DRUGCelecoxib
NSAIDS
DRUGPlacebo
Placebo
Sponsors
Sheba Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients between the age of 18 and 80 * Patients planned for elective colorectal surgery with primary anastomosis * ASA score of 1-3 * Patients that are able to sign an informed consent and comply with the protocol
Exclusion criteria
* Patients with inflammatory bowel disease * Patients that require emergency surgery * Patients with renal failure, measured by Creatinine level \> 1.5 mg/dL (\>106.1 micro mol/l) * Patients with significant liver failure (known cirrhosis, Bilirubin level\>2 mg/dL or 34.2 µmol/L) * Patients with known allergy to any medication from the non-steroidal anti-inflammatory drug group. * Patients treated chronically with any type of COX inhibitor. * Patients treated with NSAIDS including Aspirin 7 days prior to the date of surgery. * Patients with active peptic disease * Patient expected to take muscle relaxants, tricyclic antidepressants, tranquilizers, sedatives, hypnotics or neuroleptics in the postoperative period * Patient with dysphagia or that have a difficulty swallowing capsules or tablets, or is unable to tolerate oral medication * Pregnant / lactating women. * Patients participating in any other interventional clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| First flatus/bowel movement (questionnaire) | 48 to 72 hours after surgery | Reduction of time for first flatus/bowel movement from 48 hours to 72 hours in average following surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reduction of post operative ileus (questionnaire) | First week after surgery | Reduction of post-operative ileus rate in patients following colorectal surgery, treated with Celecoxib when compared with patients treated with placebo. |
| Post operative pain reduction (VAS score) | First week after surgery | Post-operative pain reduction quality in patients treated with Celecoxib when compared with patients treated with placebo following surgery. |
| Reduction of opoids consumption (registration of all medications) | First month after surgery | Reduction the amount of opioids consumed in patients treated with Celecoxib when compared with patients treated with placebo following surgery. |
| Post operative complication rate (patients follow up) | First month after surgery | Post-operative complication rate, more specifically the rate of anastomotic leakage in patients treated with Celecoxib compared with patients treated with placebo. |
Contacts
Primary ContactNir Horesh, Dr.
Outcome results
None listed